Categories AlphaGraphs, Analysis, Earnings, Health Care, LATEST

Bristol-Myers (BMY) Q3 earnings preview: New indications, pipeline to bolster recovery

Bristol-Myers Squibb (NYSE: BMY) will be publishing its September-quarter earnings Thursday before the opening bell. The bio-pharmaceutical company is expected to earn $1.07 per share on revenues of $5.89 billion, which represents a 3.5% annual increase. The fact that the bottom-line topped expectations in each of the trailing four quarters adds to the chances of another beat.

Bristol-Myers Q2 earnings, revenue top Street

Opdivo, the company’s popular immuno-oncology drug which secured the FDA’s nod for multiple indications, will be a key growth driver in the to-be-reported quarter, as it was in the previous quarter. The drug is currently prescribed widely for hepatocellular carcinoma, melanoma and a certain type of lung cancer.

Brand Power

The rapid increase in the market share of Eliquis, the blood thinner that contributed significantly to the top-line in the second quarter, is estimated to have added to growth this time too. The results should also get a boost from strong sales for the other key products, including Orencia and Sprycel, mainly in the U.S and Europe.

Related: Alexion Pharma Q3 2019 Earnings Snapshot

The market will be closely following the event for updates on Bristol-Myers’ solid pipeline and clinical trials, including the advanced-stage study on a combination of Opdivo and Yervoy for the treatment of lung cancer – which met the primary endpoint recently.

Q2 Results

In the second quarter, earnings and revenues grew in double digits to $1.18 per share and $6.3 billion, respectively, and topped expectations. However, the management revised down its full-year earnings guidance.

Celgene Deal

The post-earnings mood in the market will be crucial for the stock, which remains in the spotlight as the merger with biotech firm Celgene moves closer to completion – currently expected by year-end. Recently, Celgene agreed to sell its psoriasis drug Otezla to Amgen (AMGN), in a multi-billion deal, as required by the regulators.

Earlier this week, Pfizer (NYSE: PFE) reported lower revenues and earnings for the third quarter. The results, however, topped the market’s expectations. The management also revised up the full-year earnings and revenue guidance.

Related: Bristol-Myers Q2 2019 Earnings Conference Call Transcript

Bristol-Myers’ stock plunged to a six-year low in early July, but bounced back in the following weeks. The shares moved up 15% since the beginning of the year and 10% in the past twelve months.

We’re on Flipboard! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

Should investors worry about Micron’s (MU) weak Q4 results and guidance?

The semiconductor industry is a rapidly growing business segment that currently thrives on the digital transformation wave. The demand for memory chips and other semiconductor products increased over the years,

What has Bed Bath & Beyond (BBBY) outlined for this fiscal year?

Shares of Bed Bath & Beyond (NASDAQ: BBBY) were up on Friday, a day after the company delivered disappointing results for the second quarter of 2022. The company reported a

NKE Earnings: Highlights of Nike’s Q1 2023 results

Nike, Inc. (NYSE: NKE) has reported a decrease in net profit for the first quarter of 2023, despite a modest increase in revenues. The company's stock suffered a big loss

Add Comment
Viewing Highlight